Apeiron Capital LTD Summit Therapeutics Inc. Transaction History
Apeiron Capital LTD
- $90.5 Million
- Q3 2025
A detailed history of Apeiron Capital LTD transactions in Summit Therapeutics Inc. stock. As of the latest transaction made, Apeiron Capital LTD holds 1,310,941 shares of SMMT stock, worth $23.9 Million. This represents 30.03% of its overall portfolio holdings.
Number of Shares
1,310,941
Previous 1,200,941
9.16%
Holding current value
$23.9 Million
Previous $25.6 Million
6.34%
% of portfolio
30.03%
Previous 22.1%
Shares
2 transactions
Others Institutions Holding SMMT
# of Institutions
271Shares Held
92.9MCall Options Held
5.19MPut Options Held
3.39M-
Baker Bros. Advisors LP New York, NY33.7MShares$615 Million5.7% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.4MShares$208 Million0.0% of portfolio
-
Black Rock Inc. New York, NY7.9MShares$144 Million0.0% of portfolio
-
State Street Corp Boston, MA6.36MShares$116 Million0.0% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD4.54MShares$82.8 Million0.01% of portfolio
About Summit Therapeutics Inc.
- Ticker SMMT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 201,215,008
- Market Cap $3.67B
- Description
- Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecu...